DA-5218-C
ApprovedSmall molecule
DA-5218-C is one of 24 small molecule programs targeting Type 2 Diabetes. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
885 competitors in Type 2 Diabetes
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
DA-5218-C
DDong-A ST Co., Ltd.
Approved
Jardiance
Boehringer IngelheimPreclinical
Cysteine Hydrochloride
NovartisPreclinical
Glargine
Eli LillyPreclinical
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Aurlumyn
BBTG International Inc.
Preclinical
Pravachol
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Cecon
MMcGuff Pharmaceuticals, Inc.
Preclinical
Nexium
DDexcel Pharma Technologies Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DA-5218-C. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- DDong-A ST Co., Ltd.